COVID-19 and financial toxicity in patients with renal cell carcinoma - Top-Institutions - MDSpire

COVID-19 and financial toxicity in patients with renal cell carcinoma

By
Michael D. Staehler
Dena J. Battle
Cristiane D. Bergerot
Sumanta Kumar Pal
David F. Penson
October 22, 2020
0 min

World Journal Of Urology

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

#1

Memorial Sloan Kettering Cancer Center

New York, NY
Key Differentiators
- Genitourinary Oncology
- Health Economics
- Psychosocial Oncology
#2

Dana-Farber Cancer Institute

Boston, MA
Key Differentiators
- Medical Oncology
- Health Services Research
- Patient-Reported Outcomes
#3

MD Anderson Cancer Center

Houston, TX
Key Differentiators
- Genitourinary Oncology
- Health Economics
- Supportive Care
#4

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD
Key Differentiators
- Oncology
- Health Policy
- Patient Advocacy
#5

University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

San Francisco, CA
Key Differentiators
- Genitourinary Oncology
- Health Services Research
- Psychosocial Oncology

Original Source(s)

World Journal Of Urology

COVID-19 and financial toxicity in patients with renal cell carcinoma

by Michael D. Staehler, Dena J. Battle, Cristiane D. Bergerot, Sumanta Kumar Pal, David F. Penson
October 22, 2020

Related Content

Frontiers In Immunology

DNER drives glycolytic reprogramming in renal cell carcinoma by activating the JAK2/STAT3 signaling pathway

by Anrui Li, Jing-wen Xu, Jian-hua Qin, Qi Yuan, Lichen Teng
May 22, 2026

Bmc Cancer

Bioinformatics Investigations Uncover the Involvement of RIPK1 in Clear Cell Renal Cell Carcinoma

by Daocheng Fang, Yuanyuan Hu, Shuangquan Sun, Hui Wen, Jie Fan
February 28, 2026

Frontiers In Immunology

Deciphering the Mechanistic Landscape of Immune Checkpoint Blockade in ccRCC: From Molecular Drivers to Therapeutic Responses